secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2025-10-24T23:59:59+00:00
Accession:  0001104659-25-102137
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS Neurosciences appoints Slanix Paul Alex, Pharm.D., to board of directors
-------------------------------------------------------------------------------

- Dr. Alex is President and Portfolio Manager for Ally Bridge Group, a major shareholder; joined board effective Oct 22, 2025.
- He receives initial option for 40,000 common shares vesting 25% immediately, rest over 36 months; annual fee $40,000.
- Company highlights upcoming data readouts from PRECISE-AD trial (PMN310) in 2Q26 and 4Q26.
- Board determined Dr. Alex is independent under Nasdaq listing standards.
- Ally Bridge Group has made multiple investments in ProMIS, including July 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000110465925102137/0001104659-25-102137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000110465925102137/pmn-20251022x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-102137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer